Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2013

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2013

Jul 2013 Global Markets Direct Lymphoma156 Pages Price :
$ 2000

Global Markets Directs, Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma. Diffuse Large B-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diffuse Large B-Cell Lymphoma.
  • A review of the Diffuse Large B-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diffuse Large B-Cell Lymphoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7

Introduction 8
Global Markets Direct Report Coverage 8
Diffuse Large B-Cell Lymphoma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Diffuse Large B-Cell Lymphoma 10
Diffuse Large B-Cell Lymphoma Therapeutics under Development by Companies 12
Diffuse Large B-Cell Lymphoma Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Diffuse Large B-Cell Lymphoma Therapeutics – Products under Development by Companies 19
Diffuse Large B-Cell Lymphoma Therapeutics – Products under Investigation by Universities/Institutes 20
Companies Involved in Diffuse Large B-Cell Lymphoma Therapeutics Development 21
Amgen Inc. 21
Sanofi-Aventis 22
Eli Lilly and Company 23
Gilead Sciences, Inc. 24
Infinity Pharmaceuticals, Inc. 25
Piramal Healthcare Limited 26
Millennium Pharmaceuticals, Inc. 27
Novartis AG 28
Astellas Pharma Inc. 29
Pfizer Inc. 30
SuperGen, Inc. 31
Teva Pharmaceutical Industries Limited 32
Cell Therapeutics, Inc. 33
Celgene Corporation 34
Onyx Pharmaceuticals, Inc. 35
Accentia Biopharmaceuticals, Inc. 36
Pharmacyclics, Inc. 37
Senesco Technologies, Inc. 38
Memgen, LLC. 39
Stemline Therapeutics, Inc. 40
Onconova Therapeutics, Inc 41
Advancell 42
Diffuse Large B-Cell Lymphoma – Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 49
bendamustine hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CEP-9722 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
pacritinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
acadesine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ibrutinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
abexinostat hydrochloride - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SAR-245409 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
agatolimod sodium - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
dasiprotimut T - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
AT-7519 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
bortezomib - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
idelalisib - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ISF-35 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SL-101 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ON-013105 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
P-1446 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
buparlisib - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
palbociclib - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
lenalidomide - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
LY-2835219 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
IPI-145 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
ABT-199 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
GS-9973 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
SEL-120 Program - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
tretinoin - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
131I-Rituximab - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Andrographolide - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Diffuse Large B-Cell Lymphoma Therapeutics – Drug Profile Updates 101
Diffuse Large B-Cell Lymphoma Therapeutics – Discontinued Products 141
Diffuse Large B-Cell Lymphoma Therapeutics - Dormant Products 142
Diffuse Large B-Cell Lymphoma – Product Development Milestones 143
Featured News & Press Releases 143
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML 143
Jun 20, 2013: Acetylon Pharma Announces Presentation Of Preclinical Data Of ACY-1215 For Treatment Of Lymphoma At 12th ICML 145
Jun 19, 2013: Pharmacyclics Announces Publication Of Ibrutinib Phase II Study Results In Patients With Mantle Cell Lymphoma In New England Journal Of Medicine 146
Jun 19, 2013: Senesco Announces Results Of Cohort 2 Of Its SNS01-T Phase Ib/IIa Trial 147
Jun 16, 2013: Pharmacyclics Announces Results Of Two Phase II Ibrutinib Studies In Patients With Mantle Cell Lymphoma Or Diffuse Large B-Cell Lymphoma 148
Jun 05, 2013: Celgene Receives FDA Approval For Revlimid For Treatment Of Patients With Relapsed Or Refractory Mantle Cell Lymphoma 150
May 15, 2013: Janssen Oncology Announces Presentation Of Data On Ibrutinib At 2013 ASCO Annual Meeting 151
May 06, 2013: Janssen Announces Patient Enrolment In Ibrutinib Expanded Access Program In US 152
Apr 22, 2013: Senesco Completes Cohort 2 Of Its Phase Ib/IIa Trial Of SNS01-T 152
Apr 18, 2013: Pharmacyclics Announces Completion Of Enrollment For First Phase III Ibrutinib CLL Study And Phase II Ibrutinib MCL Study 153

Appendix 155
Methodology 155
Coverage 155
Secondary Research 155
Primary Research 155
Expert Panel Validation 155
Contact Us 156
Disclaimer 156

List of Table


Number of Products Under Development for Diffuse Large B-Cell Lymphoma, H2 2013 10
Products under Development for Diffuse Large B-Cell Lymphoma Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Amgen Inc., H2 2013 21
Sanofi-Aventis, H2 2013 22
Eli Lilly and Company, H2 2013 23
Gilead Sciences, Inc., H2 2013 24
Infinity Pharmaceuticals, Inc., H2 2013 25
Piramal Healthcare Limited, H2 2013 26
Millennium Pharmaceuticals, Inc., H2 2013 27
Novartis AG, H2 2013 28
Astellas Pharma Inc., H2 2013 29
Pfizer Inc., H2 2013 30
SuperGen, Inc., H2 2013 31
Teva Pharmaceutical Industries Limited, H2 2013 32
Cell Therapeutics, Inc., H2 2013 33
Celgene Corporation, H2 2013 34
Accentia Biopharmaceuticals, Inc., H2 2013 36
Pharmacyclics, Inc., H2 2013 37
Memgen, LLC., H2 2013 39
Stemline Therapeutics, Inc., H2 2013 40
Onconova Therapeutics, Inc, H2 2013 41
Advancell, H2 2013 42
Assessment by Monotherapy Products, H2 2013 43
Assessment by Stage and Route of Administration, H2 2013 45
Assessment by Stage and Molecule Type, H2 2013 48
Diffuse Large B-Cell Lymphoma Therapeutics Drug Profile Updates 101
Diffuse Large B-Cell Lymphoma Therapeutics Discontinued Products 141
Diffuse Large B-Cell Lymphoma Therapeutics Dormant Products 142

List of Chart


Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2013 10
Products under Development for Diffuse Large B-Cell Lymphoma Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 43
Assessment by Route of Administration, H2 2013 44
Assessment by Stage and Route of Administration, H2 2013 45
Assessment by Molecule Type, H2 2013 46
Assessment by Stage and Molecule Type, H2 2013 47

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top